Suche klinische Studie
Weitere Suchoptionen
320 Ergebnis(se)
Rekrutierende Studie = ; Fortlaufende Studie =
; Abgeschlossene Studie =
; Förderung durch ein IRDiRC-Mitglied =
; ERN-Mitglied =
Nationale klinische Studie(n)

VLAAMS BRABANT
LEUVEN
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT) - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology

Baden-Württemberg
HEIDELBERG

PREDICT: Antibakterielle Prophylaxe und Nierenparenchymschäden bei angeborenen Fehlbildungen der Nieren und ableitenden Harnwege
Zentrum für Kinder- und Jugendmedizin des Universitätsklinikums Heidelberg
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

Berlin
ADDRESS: NOT PROVIDED - DE
Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-3-Studie mit Ravulizumab bei erwachsenen und jugendlichen Teilnehmern mit thrombotischer Mikroangiopathie (TMA) nach einer hämatopoetischen Stammzelltransplantation (HSCT)t
Institution: Information not provided - DE

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT) - Ravulizumab in TMA after HSCT - ES
Institution: Information not provided - ES

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EXIST-LT: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301- BE
Universitair Ziekenhuis Brussel
Pediatric neurology / Neurologie Kinderen

VLAAMS BRABANT
LEUVEN
CRAD001M2X02B: An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304 - BE
UZ Leuven - Campus Gasthuisberg
Kinderen neurologie / Paediatric Neurology

VLAAMS BRABANT
LEUVEN

CORAL study: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children - BE
UZ Leuven - Campus Gasthuisberg
Referentiecentrum voor kindernefrologie

VLAAMS BRABANT
LEUVEN
Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria - BE
UZ Leuven - Campus Gasthuisberg
Referentiecentrum voor kindernefrologie

Baden-Württemberg
HEIDELBERG
Effectiveness and safety of mTOR-inhibitor in patients with tuberous sclerosis complex-KD
Universitätsklinikum Heidelberg

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

EXIST-3: A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures (Phase III) - FR
Institution: Information not provided - FR

ILE-DE-FRANCE
PARIS
MAGMAT : Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial (Phase III)
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service de réanimation médicale

NORMANDIE
ROUEN

PROVENCE-ALPES-COTE D'AZUR
NICE
PMNN: Personalized Medicine for Membranous Nephropathy
Faculté de médecine de Nice Sophia-Antipolis
CHU Nice

LAZIO
ROMA
Medical treatment of cystinuria
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. Follow-up del Trapianto Renale

Zuid-Holland
ROTTERDAM

RATE trial: Randomised open label cross-over study into the efficacy of rapamycin in children with Tuberous Sclerosis Complex with intractable epilepsy (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie

Zuid-Holland
ROTTERDAM

RAPIT trial: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie

WIEN
ADDRESS: NOT PROVIDED - AT


STAGED-PKD: Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Phase II-III) - AT
Institution: Information not provided - AT

WIEN
WIEN

Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study (Phase 3)
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse

Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.-GB
Institution: Information not provided - CH

Madrid
ADDRESS: NOT PROVIDED - ES
An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, in subjects with autosomal dominant polycystic kidney disease - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


A phase III, randomized, open-label active comparator-controlled multicenter study to evaluate efficacy and safety of obinutuzumab in patients with primary membranous nephropathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
RENEW: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

FALCON: A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

STAGED-PKD-EXT: Multicenter, open-label, extension study to characterize the long-term efficacy and safety of early versus delayed treatment with venglustat (GZ/SAR402671) in patients at risk of rapidly progressive autosomal dominant polycystic kidney disease (ADPKD) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
ACTION: A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase - ES
Institution: Information not provided - ES

Madrid
MADRID
Setmelanotide (RM-493): Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo

Madrid
MAJADAHONDA

Sobi.PEGCET-201: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT) - ES
Hospital Universitario Puerta de Hierro - Majadahonda
Servicio de Hematología y Hemoterapia

Indiana
INDIANAPOLIS

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney (Phase II) - US
Indiana University School of Medicine

Minnesota
ROCHESTER

Greater Manchester
ADDRESS: NOT PROVIDED - UK
A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children-GB
Institution: Information not provided - UK

Greater Manchester
ADDRESS: NOT PROVIDED - UK

Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria-GB
Institution: Information not provided - UK

West Midlands
BIRMINGHAM

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - BE
Erasme Hospital - ULB
Néphrologie

Baden-Württemberg
ULM

Kombinierte klinische Studie der Phasen 1 und 1/2a zur Bewertung der Sicherheit und Wirksamkeit einer autologen Muskel-Stammzelltherapie bei der Behandlung von Harninkontinenz bei isolierter Epispadie
Universitätsklinikum Ulm am Michelsberg
Klinik für Kinderurologie

Bayern
MÜNCHEN

Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum

Bayern
MÜNCHEN


SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
TUM Fakultät für Medizin

Bayern
MÜNCHEN


SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
kbo-Kinderzentrum München gemeinnützige GmbH
kbo-Kinderzentrum München

Bayern
REGENSBURG

Kombinierte klinische Studie der Phasen 1 und 1/2a zur Bewertung der Sicherheit und Wirksamkeit einer autologen Muskel-Stammzelltherapie bei der Behandlung von Harninkontinenz bei isolierter Epispadie
Krankenhaus Barmherzige Brüder Regensburg - Klinik St. Hedwig
Klinik für Kinderurologie

Berlin
ADDRESS: NOT PROVIDED - DE

ACCOLADE: Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Untersuchung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie
Institution: Information not provided - DE

Berlin
BERLIN

Kombinierte klinische Studie der Phasen 1 und 1/2a zur Bewertung der Sicherheit und Wirksamkeit einer autologen Muskel-Stammzelltherapie bei der Behandlung von Harninkontinenz bei isolierter Epispadie
Charité / Max-Delbrück-Centrum für Molekulare Medizin
Muskelforschung mit Hochschulambulanz für Muskelkrankheiten

Hamburg
HAMBURG
COMMUTE-a: Eine multizentrische, einarmige Phase-III-Studie zur Bewertung der Wirksamkeit, Sicherheit, Pharmakokinetik und Pharmakodynamik von Crovalimab bei erwachsenen und jugendlichen Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS)
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Kinder- und Jugendmedizin

Niedersachsen
GÖTTINGEN


EARLY PRO-TECT Alport: Prospektive, randomisierte, Placebo-kontrollierte, doppelblinde, Industrie-unabhängige, multizentrische Studie mit ACE-Hemmer Ramipril versus Placebo bei frühen Stadien des Alport Syndroms: optimaler Therapiestart und Sicherheit (Phase III)
Universitätsmedizin Göttingen
Klinik für Nephrologie und Rheumatologie

Niedersachsen
HANNOVER
COMMUTE-a: Eine multizentrische, einarmige Phase-III-Studie zur Bewertung der Wirksamkeit, Sicherheit, Pharmakokinetik und Pharmakodynamik von Crovalimab bei erwachsenen und jugendlichen Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS)
Medizinische Hochschule Hannover
Klinik für Nieren- und Hochdruckerkrankungen

Niedersachsen
HANNOVER

Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)

Nordrhein-Westfalen
BONN
EyNeP: Intravitreales Aflibercept (Eylea®) zur Therapie von choroidalen Neovaskularisationen und fibrovaskulären Proliferationen in Patienten mit Pseudoxanthoma elasticum (Phase II)
Universitäts-Augenklinik Bonn

Nordrhein-Westfalen
ESSEN
COMMUTE-a: Eine multizentrische, einarmige Phase-III-Studie zur Bewertung der Wirksamkeit, Sicherheit, Pharmakokinetik und Pharmakodynamik von Crovalimab bei erwachsenen und jugendlichen Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS)
Universitätsklinikum Essen
Klinik für Kinderheilkunde II

Nordrhein-Westfalen
ESSEN
COMMUTE-a: Eine multizentrische, einarmige Phase-III-Studie zur Bewertung der Wirksamkeit, Sicherheit, Pharmakokinetik und Pharmakodynamik von Crovalimab bei erwachsenen und jugendlichen Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS)
Universitätsklinikum Essen
Klinik für Nephrologie

Nordrhein-Westfalen
ESSEN

Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Universitätsklinikum Essen

Nordrhein-Westfalen
KÖLN
COMMUTE-a: Eine multizentrische, einarmige Phase-III-Studie zur Bewertung der Wirksamkeit, Sicherheit, Pharmakokinetik und Pharmakodynamik von Crovalimab bei erwachsenen und jugendlichen Patienten mit atypischem hämolytisch-urämischem Syndrom (aHUS)
Universitätsklinikum Köln
Klinik II für Innere Medizin - Nephrologie, Rheumatologie, Diabetologie und allgemeine Innere Medizin

Sachsen
DRESDEN

Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden

Schleswig-Holstein
LÜBECK

Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Bewertung der Sicherheit und Wirksamkeit von Avacopan (CCX168) bei Patienten mit C3-Glomerulopathie.
Universitätsklinikum Schleswig-Holstein - Campus Lübeck

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A multicentre, open-label, extension study, evaluating the safety and tolerability and the efficacy of ADV7103 at long term in distal renal tubular acidosis patients (Phase III) - FR
Institution: Information not provided - FR

PAYS DE LA LOIRE
NANTES
STOPECU : Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS) (Phase IV)
CHU de Nantes - Hôtel Dieu
Service de néphrologie et immunologie clinique

LOMBARDIA
MILANO
A Phase 2 Open-label Study to Evaluate the Efficacy of Allogeneic Human Cord Blood-derived Mesenchymal Stromal Cells in Maintaining Remission After Immunosuppressive Therapy Withdrawal in Pediatric Patients With Steroid-dependent Nephrotic Syndrome
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
U.O.C. di Nefrologia, Dialisi e Trapianto Pediatrico

LOMBARDIA
MILANO

An open-label, multi-center clinical trial of eculizumab in pediatric patients with atypical hemolytic-uremic syndrome (aHUS) (Phase II) - IT
IRCCS Ca' Granda Ospedale Maggiore Policlinico - Padiglione De Marchi
Centro per la Cura e lo Studio della Sindrome Emolitico Uremica (Center for HUS Control)

Gelderland
NIJMEGEN

An open-label, multi-center clinical trial of eculizumab in pediatric patients with atypical hemolytic-uremic syndrome (aHUS) (Phase II) - NL
Radboudumc - Radboud universitair medisch centrum
Afdeling Kindernefrologie

Zuid-Holland
ROTTERDAM


NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie

Zuid-Holland
ROTTERDAM


NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Neurowetenschappen

WIEN
ADDRESS: NOT PROVIDED - AT
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

APPELHUS: A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy (Phase 3) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

NOBLE: An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN - AT
Institution: Information not provided - AT

WIEN
WIEN
Post-HERCULES: Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Phase III) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

WIEN
WIEN

A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2-period Crossover Study With a Single Arm Continuation Evaluating the Safety and Efficacy of BAX 930 (rADAMTS13) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

WIEN
WIEN


A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS-13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

WIEN
WIEN

A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Nephrologie und Gastroenterologie

WIEN
WIEN

SOAR-HI: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment - ES
Baxalta - Baxter Innovations GmbH Austria

Region Skåne
LUND

plexifpc - Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief - SE
Skåne University Hospital, Lund

Andalucía
MÁLAGA

Response to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) - ES
Hospital Universitario Virgen de la Victoria
Unidad de Medicina Interna

Madrid
ADDRESS: NOT PROVIDED - ES


A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2-period Crossover Study With a Single Arm Continuation Evaluating the Safety and Efficacy of BAX 930 (rADAMTS13) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
OPTIMAB: Pilot study for the optimitzation of the maintenance dose of eculizumab according to the weight in adult patients with atypic hemolytic uremic syndrome - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

SOAR-HI: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


HERA: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


COMMUTE-a: A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult and pediatric participants with neurofibromatosis type 1 - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


COMMUTE-p: A phase III, open-label, multicenter, single-arm study evaluating the efficacy and safety of crovalimab in adolescent and pediatric patients with atypical hemolytic uremic syndrome (aHUS) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

NOBLE: An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

APPEAR-C3G: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

EPPIK: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
VALIANT: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - ES
Institution: Information not provided - ES

País Vasco
BARAKALDO

Greater London
LONDON

A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital

Greater London
LONDON
A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -GB
St Bartholomew's Hospital, Barts and The London NHS Trust
Barts & The London NHS Trust

Tyne & Wear
NEWCASTLE UPON TYNE


Multicentre, open label, prospective, single arm study of the safety and impact of Eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome
Institute of Cellular Medicine, Newcastle University, Medical School
Institute of Cellular Medicine

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

VAIN study: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome - BE
Universitair Ziekenhuis Brussel
Nefrologie dienst / Nephrology department

OOST-VLAANDEREN
GENT
SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE
Ghent University Hospital - UZ Gent
Department of Rheumatology

Baden-Württemberg
HEIDELBERG

Die VITAL-Amyloidose-Studie: Eine randomisierte, multizentrische, doppelblinde, Placebo-kontrollierte, 2-armige Phase 3-Studie zur Untersuchung der Wirksamkeit und Sicherheit von NEOD001 plus Standardtherapie im Vergleich zu Placebo plus Standardtherapie bei Patienten mit Leichtketten- (AL-) Amyloidose
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Baden-Württemberg
HEIDELBERG

Eine randomisierte, kontrollierte, offene, multizentrische Phase III-Studie zur Untersuchung der Sicherheit und Wirksamkeit von Dexamethason plus MLN9708 im Vergleich zur Therapie nach Wahl des Arztes bei Patienten mit rezidivierender oder refraktärer systemischer Leichtketten- (AL-) Amyloidose
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Baden-Württemberg
HEIDELBERG

Eine randomisierte, multizentrische Phase III-Studie zum Vergleich einer Behandlung mit Melphalan und Dexamethason und mit Bortezomib-Melphalan-Dexamethason bei unbehandelten Patienten mit systemischer Leichtketten(AL)-Amyloidose
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Baden-Württemberg
HEIDELBERG
Eine offene Phase-1/2-Studie von Melflufen und Dexamethason für Patienten mit Al-Amyloidose nach mindestens einer vorherigen Therapielinie
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Baden-Württemberg
HEIDELBERG


ReDox: Randomisierte Phase II/III Studie mit Doxycyclin oder einer Standard Supportivtherapie bei neu diagnostizierten Patienten mit kardialer Leichtketten (AL-) Amyloidose, die mit einer Bortezomib-haltigen Chemotherapie behandelt werden
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Baden-Württemberg
HEIDELBERG
Eine Phase-2-Studie zu Belantamab Mafodotin bei Patienten mit rezidivierter oder therapieresistenter AL-Amyloidose
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

Baden-Württemberg
HEIDELBERG


INTENT-Studie: Randomisierte, kontrollierte, multizentrische Therapiestudie zur Initialtherapie der Erstmanifestation des idiopathischen nephrotischen Syndroms im Kindesalter mit Mycophenolatmofetil versus Prednison
Zentrum für Kinder- und Jugendmedizin des Universitätsklinikums Heidelberg
Klinik für Kinderheilkunde I - Sektion Pädiatrische Nephrologie

Baden-Württemberg
TÜBINGEN

TOFFIFE: Tocilizumab zur Behandlung des Familiären Mittelmeerfiebers - Eine randomisierte, doppelblinde Phase II Studie
Interdisziplinäres Rheumazentrum (INDIRA)
Zentrum für Interdisziplinäre Rheumatologie, klinische Immunologie und Autoimmunerkrankungen

Berlin
ADDRESS: NOT PROVIDED - DE
PRESIDIO: Eine randomisierte, doppelblinde, placebokontrollierte Crossover multizentrische Phase 2-Studie zur Bewertung der Sicherheit und Wirksamkeit von KZR-616 bei der Behandlung von Patienten mit aktiver Polymyositis oder Dermatomyositis
Institution: Information not provided - DE

Berlin
BERLIN

CAEL101-301: Eine doppelblinde, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von CAEL-101 und Plasmazelldyskrasie-Behandlung im Vergleich zu Placebo und Plasmazelldyskrasie-Behandlung bei therapienaiven Plasmazelldyskrasie-Patienten mit AL-Amyloidose im Stadium IIIb nach Mayo
Charité - Universitätsmedizin Berlin

Berlin
BERLIN

CAEL101-302: Eine doppelblinde, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von CAEL-101 und Plasmazelldyskrasie-Behandlung im Vergleich zu Placebo und Plasmazelldyskrasie-Behandlung bei therapienaiven Plasmazelldyskrasie-Patienten mit AL-Amyloidose im Stadium IIIa nach Mayo
Charité - Universitätsmedizin Berlin

Berlin
BERLIN

The RECLAIIM Study: Eine Studie zur Bewertung der Wirksamkeit, Sicherheit und Pharmakokinetik von IgPro20 (subkutanes Immunglobulin, Hizentra®) bei Erwachsenen mit Dermatomyositis (DM)
Charité - Universitätsmedizin Berlin

Berlin
BERLIN

CONSIDER: Eine multizentrische, Placebo-kontrollierte Phase II-Studie mit Canakinumab zur Behandlung des Adulten Still-Syndroms
Charité - Universitätsmedizin Berlin (CCM)
Autoinflammation Reference Center Charité (ARC²)

Hessen
BAD NAUHEIM
wiRASSc: Einfluss der seriellen lokoregionalen wassergefilterten Infrarot A Strahlung zusätzlich zu einer multimodalen Standardtherapie bei systemischer Sklerose und Raynaud Syndrom der Hände
Kerckhoff-Klinik GmbH
Abteilung für Rheumatologie und klinische Immunologie

Niedersachsen
HANNOVER
SENSCIS (TM) Extension: Eine offene Verlängerungsstudie zur Beurteilung der Langzeitsicherheit von Nintedanib bei Patienten mit Systemischer Sklerose assoziierter Interstitieller Lungenerkrankung (SSc-ILD).
Medizinische Hochschule Hannover
Klinik für Pneumologie

Nordrhein-Westfalen
ESSEN

CAEL101-301: Eine doppelblinde, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von CAEL-101 und Plasmazelldyskrasie-Behandlung im Vergleich zu Placebo und Plasmazelldyskrasie-Behandlung bei therapienaiven Plasmazelldyskrasie-Patienten mit AL-Amyloidose im Stadium IIIb nach Mayo
Universitätsklinikum Essen
Klinik für Neurologie

Nordrhein-Westfalen
ESSEN

CAEL101-302: Eine doppelblinde, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von CAEL-101 und Plasmazelldyskrasie-Behandlung im Vergleich zu Placebo und Plasmazelldyskrasie-Behandlung bei therapienaiven Plasmazelldyskrasie-Patienten mit AL-Amyloidose im Stadium IIIa nach Mayo
Universitätsklinikum Essen
Klinik für Neurologie

Nordrhein-Westfalen
ESSEN

The RECLAIIM Study: Eine Studie zur Bewertung der Wirksamkeit, Sicherheit und Pharmakokinetik von IgPro20 (subkutanes Immunglobulin, Hizentra®) bei Erwachsenen mit Dermatomyositis (DM)
Universitätsklinikum Essen
Klinik für Neurologie

Nordrhein-Westfalen
KÖLN

The RECLAIIM Study: Eine Studie zur Bewertung der Wirksamkeit, Sicherheit und Pharmakokinetik von IgPro20 (subkutanes Immunglobulin, Hizentra®) bei Erwachsenen mit Dermatomyositis (DM)
Universitätsklinikum Köln

Nordrhein-Westfalen
MÜNSTER

CAEL101-301: Eine doppelblinde, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von CAEL-101 und Plasmazelldyskrasie-Behandlung im Vergleich zu Placebo und Plasmazelldyskrasie-Behandlung bei therapienaiven Plasmazelldyskrasie-Patienten mit AL-Amyloidose im Stadium IIIb nach Mayo
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A

Nordrhein-Westfalen
MÜNSTER

CAEL101-302: Eine doppelblinde, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von CAEL-101 und Plasmazelldyskrasie-Behandlung im Vergleich zu Placebo und Plasmazelldyskrasie-Behandlung bei therapienaiven Plasmazelldyskrasie-Patienten mit AL-Amyloidose im Stadium IIIa nach Mayo
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A

Nordrhein-Westfalen
MÜNSTER

The RECLAIIM Study: Eine Studie zur Bewertung der Wirksamkeit, Sicherheit und Pharmakokinetik von IgPro20 (subkutanes Immunglobulin, Hizentra®) bei Erwachsenen mit Dermatomyositis (DM)
Universitätsklinikum Münster

Sachsen-Anhalt
DESSAU

Eine Phase 3, multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte, Parallelgruppen-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Apremilast (CC-10004) bei Patienten mit aktiver Behcet-Krankheit
Städtisches Klinikum Dessau
Klinik für Dermatologie, Venerologie und Allergologie / Immunologisches Zentrum

Finland
TURKU

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI-
Turku University Hospital
Turku PET CENTRE

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR
Institution: Information not provided - FR

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -FR
Institution: Information not provided - FR

BRETAGNE
RENNES

SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
CHU de Rennes - Hôpital Pontchaillou
Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire

ILE-DE-FRANCE
PARIS

MSC: Treatment of Refractory Severe Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells - (Phase I-II) - FR
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

ILE-DE-FRANCE
PARIS
ITAC: Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease.
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière
Département de Médecine Interne et Immunologie Clinique (DMIIC)

ILE-DE-FRANCE
PARIS

NEPHROMYCY - Cyclophosphamide versus mycophenolate mofetil for children with steroid-dependent idiopathic nephrotic syndrome : a multicenter randomized controlled trial (Phase III).
CHU Paris - Hôpital Robert Debré
Service de Néphrologie - Hémodialyse

ILE-DE-FRANCE
PARIS

NEPHROVIR3 : A Multicenter, Randomised, Double-blind Placebo-controlled Trial Assessing the Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children (Phase III)
CHU Paris - Hôpital Robert Debré
Service de Néphrologie - Hémodialyse

NOUVELLE AQUITAINE
LIMOGES
AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR
CHU de Limoges - Hôpital Dupuytren
Service d'hématologie clinique et de thérapie cellulaire

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

SCLERADEC III : SCLERoderma and Adipose-DErived Stroma Cells (Phase II)
CHU de Marseille - Hôpital Nord
Service de Médecine Interne

County Dublin
DUBLIN

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - IE
Beaumont Hospital
Kidney Centre

County Dublin
DUBLIN
SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE
St. Vincent's University Hospital
CF Clinic

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III)
Institution: Information not provided - IT

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
OFA3: Efficacy of humanized anti-CD20 antibodies (Ofatumumab) in the treatment of childhood steroid-dependent nephrotic syndrome and development of cell biomarkers predicting outcome
Institution: Information not provided - IT

EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy - IT
Institution: Information not provided - IT

LAZIO
ROMA
Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE SAN PAOLO
Laboratorio di Nefrologia - Divisione di Nefrologia e Dialisi

LIGURIA
GENOVA
Five-year actively controlled clinical trial in new onset juvenile dermatomyositis
IRCCS Istituto G. Gaslini - Ospedale Pediatrico
U.O. Pediatria II

LOMBARDIA
PAVIA

A randomized open-label multicenter phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis - IT
Fondazione IRCCS Policlinico San Matteo
Laboratorio di Biotecnologie e Tecnologie Biomediche

LOMBARDIA
PAVIA


A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - IT
Fondazione IRCCS Policlinico San Matteo
Dipartimento di Medicina Molecolare

TOSCANA
FIRENZE
ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) - IT
AOU Careggi
Dipartimento di Biomedicina

Gelderland
NIJMEGEN
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone
Radboudumc - Radboud universitair medisch centrum
Afdeling Nierziekten

Noord-Holland
AMSTERDAM
Levamisole treatment for children with steroid sensitive nephrotic syndrome. An international multi-centre, double-blind, placebo-controlled, randomised trial
Amsterdam UMC, locatie AMC
Polikliniek Kindernefrologie

Noord-Holland
AMSTERDAM

IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC
Afdeling Neurologie

Utrecht
ADDRESS: NOT PROVIDED - NL

A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc) - NL
Institution: Information not provided - NL

Utrecht
UTRECHT

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II)
UMC Utrecht - Universitair Medisch Centrum Utrecht
Afdeling Nefrologie

WIEN
ADDRESS: NOT PROVIDED - AT

SENSCIS(R)-ON: An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT
Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis - AT
Institution: Information not provided - AT

CENTRO
ADDRESS: NOT PROVIDED - PT

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - PT
Institution: Information not provided - PT

Region Skåne
LUND

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy - SE
Skåne University Hospital, Lund

Suisse Romande
ADDRESS: NOT PROVIDED - CH
SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - CH
Institution: Information not provided - CH

Cataluña
BARCELONA
An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES
Hospital Clínic de Barcelona
Servicio de Hematología

Cataluña
BARCELONA


ReDox: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ES
Hospital Clínic de Barcelona
Servicio de Hematología

Cataluña
BARCELONA
DETERMINE: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis - ES
Hospital Universitari Vall d'Hebron
Servicio de Medicina Interna

Madrid
ADDRESS: NOT PROVIDED - ES
SENSCIS (TM)-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

RECLAIIM: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


A phase 2 double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of PF-06823859 in adult subjects with dermatomyositis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

AFFIRM-AL: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

EMERALD: A two-cohort, open-label, single arm, multicenter study to evaluate [...] emapalumab in children and adults with macrophage activation syndrome (MAS) in Still's disease (including systemic juvenile idiopathic arthritis and Adult onset Still's disease) or with MAS in Systemic lupus erythematous - ES
Institution: Information not provided - ES

TUNISIA
ADDRESS: NOT PROVIDED - TN

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TN
Institution: Information not provided - TN

TURKEY
ADDRESS: NOT PROVIDED - TR

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - TR
Institution: Information not provided - TR

Közép-Magyarország
BUDAPEST

A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Institute of Genomic Medicine and Rare Disorders, Semmelweis University
Genetics Laboratory

Maryland
BALTIMORE


Study of Growth Hormone Use in Patients With Pseudohypoparathyroidism Type 1a (Subtype of Albright Hereditary Osteodystrophy) (Phase 2/3) - US
Kennedy Krieger Institute

New Jersey
BORDENTOWN

Pennsylvania
PHILADELPHIA

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis - US
University of Pennsylvania
Perelman School of Medicine

Washington
SEATTLE

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
University of Washington

Cardiff
CARDIFF

Developing a non-invasive treatment for twin-twin transfusion syndrome
Centre for Trials Research

Greater London
ADDRESS: NOT PROVIDED - GB

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -GB
Institution: Information not provided - GB

Greater London
LONDON

Developing a non-invasive treatment for twin-twin transfusion syndrome
Imperial College London
Institute of Reproductive and Developmental Biology

Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit

Greater Manchester
ADDRESS: NOT PROVIDED - UK
SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB
Institution: Information not provided - UK

Greater Manchester
SALFORD
Cold Challenge With C21 in RP
Salford Royal NHS Foundation Trust
University of Manchester Rheumatic Diseases Centre

ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis - BE
Institution: Information not provided - BE

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

THEIA: Une étude de phase 2, multicentrique, randomisée, contrôlée contre placebo, en double aveugle, de validation de principe pour évaluer le Guselkumab pour le traitement des participants atteints d'artérite à cellules géantes d'apparition récente ou récidivante - BE
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc

LIEGE
LIEGE
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis (Phase II) - BE
CHU de Liège - Site du Sart Tilman
CHU de Liège (ULG)

OOST-VLAANDEREN
GENT

NOVESA study: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis - BE
Ghent University Hospital - UZ Gent
Department of Rheumatology

VLAAMS BRABANT
LEUVEN

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
UZ Leuven - Campus Gasthuisberg
UZ Leuven

Baden-Württemberg
FREIBURG
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
Universitätsklinikum Freiburg
Klinik für Rheumatologie und Klinische Immunologie

Baden-Württemberg
FREIBURG
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Freiburg

Baden-Württemberg
HEIDELBERG
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Heidelberg

Baden-Württemberg
KIRCHHEIM UNTER TECK

THEIA: Eine multizentrische, randomisierte, placebokontrollierte, doppelblinde Phase-2-Studie zum Nachweis der Wirksamkeit von Guselkumab bei der Behandlung von Teilnehmern mit neu auftretender oder schubförmiger Riesenzellarteriitis
medius Klinik Kirchheim
Klinik für Innere Medizin, Rheumatologie und Immunologie

Baden-Württemberg
MANNHEIM

Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim

Baden-Württemberg
TÜBINGEN

AST-MOMA: Hochdosis-Chemotherapie und Transplantation von CD34-selektionierten Stammzellen bei progressiver systemischer Sklerose - Modifikation nach Manifestation (Phase II)
Interdisziplinäres Rheumazentrum (INDIRA)
Zentrum für Interdisziplinäre Rheumatologie, klinische Immunologie und Autoimmunerkrankungen

Baden-Württemberg
TÜBINGEN

ISLAND-SLE: Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie mit LY3471851 (NKTR-358) bei Erwachsenen mit systemischem Lupus erythematodes
Interdisziplinäres Rheumazentrum (INDIRA)
Zentrum für Interdisziplinäre Rheumatologie, klinische Immunologie und Autoimmunerkrankungen

Baden-Württemberg
TÜBINGEN

THEIA: Eine multizentrische, randomisierte, placebokontrollierte, doppelblinde Phase-2-Studie zum Nachweis der Wirksamkeit von Guselkumab bei der Behandlung von Teilnehmern mit neu auftretender oder schubförmiger Riesenzellarteriitis
Universitätsklinikum Tübingen

Baden-Württemberg
ULM
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Ulm

Bayern
ERLANGEN
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Internistisches Zentrum des Universitätsklinikums Erlangen
Medizinische Klinik 3 - Rheumatologie und Immunologie

Bayern
ERLANGEN

THEIA: Eine multizentrische, randomisierte, placebokontrollierte, doppelblinde Phase-2-Studie zum Nachweis der Wirksamkeit von Guselkumab bei der Behandlung von Teilnehmern mit neu auftretender oder schubförmiger Riesenzellarteriitis
Universitätsmedizin Erlangen
Universitätsklinikum Erlangen

Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Langzeitzugangsprogramm für Probanden, die an der Studie MEA115921 (Placebo-kontrollierte Studie von Mepolizumab zur Behandlung von eosinophiler Granulomatose mit Polyangiitis bei Probanden mit Standardtherapie) teilgenommen haben. - DE-
Institution: Information not provided - DE

Berlin
ADDRESS: NOT PROVIDED - DE

SELUNE: Eine zweijährige, randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie der Phase III zur Untersuchung der Sicherheit, Wirksamkeit und Verträglichkeit von 300 mg secukinumab s.c. im Vergleich zu Placebo in Kombination mit einer SoC-Therapie bei Patienten mit aktiver Lupusnephritis
Institution: Information not provided - DE

Berlin
BERLIN

Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Charité - Universitätsmedizin Berlin

Berlin
BERLIN
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie

Berlin
BERLIN
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
Charité - Universitätsmedizin Berlin (CCM)
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie

Hamburg
HAMBURG

Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Schön Klinik Hamburg Eilbek
Hamburger Zentrum für Kinder- und Jugendrheumatologie

Hamburg
HAMBURG

ISLAND-SLE: Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie mit LY3471851 (NKTR-358) bei Erwachsenen mit systemischem Lupus erythematodes
UKE - Universitätsklinikum Hamburg-Eppendorf
III. Medizinische Klinik und Poliklinik

Hessen
BAD NAUHEIM

Hessen
FRANKFURT AM MAIN
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Universitätsklinikum Frankfurt
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt

Niedersachsen
HANNOVER
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Medizinische Hochschule Hannover
Klinik für Nieren- und Hochdruckerkrankungen

Niedersachsen
HANNOVER

THEIA: Eine multizentrische, randomisierte, placebokontrollierte, doppelblinde Phase-2-Studie zum Nachweis der Wirksamkeit von Guselkumab bei der Behandlung von Teilnehmern mit neu auftretender oder schubförmiger Riesenzellarteriitis
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)

Nordrhein-Westfalen
ESSEN

Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Essen

Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Universitätsklinikum Essen

Nordrhein-Westfalen
HERNE
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
St. Josefs-Krankenhaus
Rheumazentrum Ruhrgebiet

Nordrhein-Westfalen
KÖLN
Eine randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Studie zur Beurteilung der Sicherheit und Wirksamkeit einer Behandlung mit Branebrutinib bei Teilnehmern mit aktivem systemischem Lupus erythematodes oder primärem Sjögren-Syndrom oder einer Behandlung mit Branebrutinib, gefolgt von einer offenen Behandlung mit Abatacept bei Teilnehmern mit aktiver rheumatoider Arthritis
Universitätsklinikum Köln
Klinik I für Innere Medizin

Nordrhein-Westfalen
KÖLN

ISLAND-SLE: Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie mit LY3471851 (NKTR-358) bei Erwachsenen mit systemischem Lupus erythematodes
Universitätsklinikum Köln
Klinik I für Innere Medizin

Nordrhein-Westfalen
KÖLN
RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Köln
Klinik und Poliklinik für Dermatologie und Venerologie

Nordrhein-Westfalen
MÜNSTER

Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Münster

Nordrhein-Westfalen
SANKT AUGUSTIN

Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Asklepios Kinderklinik Sankt Augustin GmbH
Abteilung für Allgemeine Kinder- und Jugendmedizin

Rheinland-Pfalz
MAINZ
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Sicherheit und Wirksamkeit von BMS-986165 mit einer Hintergrundbehandlung bei Teilnehmern mit Lupus-Nephritis
Universitätsmedizin Mainz

Sachsen
DRESDEN

Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden

Schleswig-Holstein
KIEL

ISLAND-SLE: Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie mit LY3471851 (NKTR-358) bei Erwachsenen mit systemischem Lupus erythematodes
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Klinik für Innere Medizin I

Thüringen
JENA

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) - FR
Institution: Information not provided - FR

AUVERGNE-RHONE-ALPES
PIERRE-BENITE

MAINEPSAN Study: A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of Prednisone in Systemic anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire

BOURGOGNE-FRANCHE-COMTE
DIJON
METOGiA: MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
CHU Dijon Bourgogne - Hôpital François Mitterrand
Service de médecine interne et immunologie clinique

ILE-DE-FRANCE
ISSY-LES-MOULINEAUX

INTOReTAK: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis.
Hôpital Corentin-Celton
Service de Réadaptation vasculaire

ILE-DE-FRANCE
PARIS

MSC-LES: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

ILE-DE-FRANCE
PARIS

CHUSPAN2 : Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Churg Strauss Syndrome Without Poor Prognosis Factors (Phase III)
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares

ILE-DE-FRANCE
PARIS
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement (ToGiAC)
AP-HP.Sorbonne Université - Hôpital Saint-Antoine
Service de Neurologie

ILE-DE-FRANCE
PARIS

TOCITAKA : Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study (Phase III)
AP-HP.Sorbonne Université - Hôpital Saint-Antoine
Service de médecine interne

PROVENCE-ALPES-COTE D'AZUR
NICE
CECIBO: Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis
Faculté de médecine de Nice Sophia-Antipolis
CHU Nice

County Galway
GALWAY

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma - IE
University Hospital Galway
Department of Haematology

PUGLIA
BARI

Combined Therapy With Peg-Interferon alpha, Ribavirin And Rituximab Of Hepatitis C Virus-Related Mixed Cryoglobulinemia - IT
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica

JAPAN
ADDRESS : NOT PROVIDED - JP
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus - JP
Institution: Information not provided - JP

JAPAN
HYOGO

BRAVE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - JP
Eli Lilly Japan K.K.

Groningen
GRONINGEN


Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie

WIEN
ADDRESS: NOT PROVIDED - AT
A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis (Phase 2) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

BRAVE I: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

SLE-BRAVE-X: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

SELECT-GCA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis (Phase 3) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis (Phase 3) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

PHOENYCS GO: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (Phase 3) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis (Phase 2) - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy - AT
Institution: Information not provided - AT

WIEN
ADDRESS: NOT PROVIDED - AT

SELUNE: A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy and tolerability of 300mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis - AT
Institution: Information not provided - AT

WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse

Warszawa
WARSAW

A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) In Subjects with Diffuse Cutaneous Systemic Sclerosis with Interstitial Lung Disease - PL
Instytut Reumatologii im. prof. dr hab. med. Eleonory Reicher
Klinika I Poliklinika Ukladowych Chorob Tkanki Lacznej

Suisse Romande
ADDRESS: NOT PROVIDED - CH

SELUNE: A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy and tolerability of 300mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis - CH
Institution: Information not provided - CH

Cataluña
BARCELONA

ABROGATE: Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener's) - ES
Hospital Clínic de Barcelona

Madrid
ADDRESS: NOT PROVIDED - ES

A multi-center, open-label trial to evaluate the pharmacokinetics, safety, and pharmacodynamics of subcutaneously administered belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric participants with systemic lupus erythematosus (SLE) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
PROTECT: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
NefIgArd: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

THEIA: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

ISLAND-SLE: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

SELUNE: A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy and tolerability of 300mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

ARTEMIS - IGAN: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Sclerosis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in participants with diffuse systemic sclerosis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

SLE-BRAVE-X: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


A phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose ranging study to evaluate the efficacy and safety profile of PF-06700841 in participants with active systemic lupus erythematosus (SLE) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

PHOENYCS GO: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

Tulip SC: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

RECAST SLE: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES


ALLEGORY: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of obinutuzumab in patients with systemic lupus erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

TOPAZ-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

Synergy: A randomized, double-blind, placebo-controlled study of ALPN-101 in systemic lupus erythematosus - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

SELECT-GCA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE) - ES
Institution: Information not provided - ES

Madrid
ADDRESS: NOT PROVIDED - ES

APATURA: Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus: A randomized, double blind, placebo-controlled, Phase 2, proof of concept study - ES
Institution: Information not provided - ES

Pennsylvania
PITTSBURGH

TAMER: The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis (Phase II) - US
University of Pittsburgh

Cambridgeshire
CAMBRIDGE

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis-GB
Addenbrooke's Hospital
Addenbrookes Hospital

Cambridgeshire
CAMBRIDGE

Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
Addenbrooke's Hospital
Addenbrookes Hospital

Cambridgeshire
CAMBRIDGE

Biologics in refractory vasculitis
University of Cambridge
Department of Medicine

Derbyshire
CHESTERFIELD

PRedSS:A Phase II Randomised Controlled Study of Oral Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis -GB
Copeman House
Versus Arthritis (formerly Arthritis Research UK)

Greater London
LONDON
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis-GB
University College London Medical School and Royal Free Hospital
Metabolic Bone Disease - Centre for Rheumatology and Connective Tissue Diseases

Tayside
DUNDEE
RESOLVE-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis-GB
Ninewells Hospital and Medical School
Multinationale klinische Studie(n)

Suisse Alémanique
BASEL
EXIST-2: Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Novartis International AG

Suisse Alémanique
BASEL

Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.
Institution: Information not provided - CH

Massachusetts
CAMBRIDGE

OOST-VLAANDEREN
ZWIJNAARDE

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A multicentre, open-label, extension study, evaluating the safety and tolerability and the efficacy of ADV7103 at long term in distal renal tubular acidosis patients.
Institution: Information not provided - FR

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A multicentre, open-label, non-inferiority sequential study, evaluating the efficacy, safety, tolerability and acceptability of ADV7103 compared to standard of care in distal renal tubular acidosis patients.
Institution: Information not provided - FR

ILE-DE-FRANCE
LEVALLOIS-PERRET
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Europe SAS

Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.

Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.

Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.

Connecticut
CHESHIRE
An open-label, multi-center controlled clinical trial of eculizumab in adolescent patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) (Phase II) (coordination)
Alexion Pharmaceuticals, Inc.

Connecticut
CHESHIRE
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc.

Pennsylvania
WAYNE
SOAR-HI: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-blind Study in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) to Evaluate the Pharmacokinetics,Safety and Efficacy of rADAMTS-13 (SHP655) Administered in Addition to Standard Of Care (SoC) Treatment
Shire Development LLC and International Affiliates

Berlin
ADDRESS: NOT PROVIDED - DE
SENSCIS : A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Institution: Information not provided - DE

County Dublin
ADDRESS: NOT PROVIDED - IE
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (Prematurely ended)
Institution: Information not provided - IE

LOMBARDIA
PAVIA
A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
Fondazione IRCCS Policlinico San Matteo
Dipartimento di Medicina Molecolare

Region Stockholm
STOCKHOLM
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
Oncopeptides AB

Suisse Alémanique
BASEL

TURKEY
ISTANBUL
EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) (TERMINATED)
Acibadem University
Department of ophtalmology

California
SOUTH SAN FRANCISCO
PRESIDIO: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyositis
Kezar Life Sciences, Inc.

Maryland
GAITHERSBURG

Pennsylvania
PHILADELPHIA
An Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMF
Mutual Pharmaceutical Company, Inc.

Washington
ADDRESS: NOT PROVIDED - US
International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
AMYDARA: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis.
Institution: Information not provided - US

Greater London
LONDON
ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous poulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) (coordination) - terminated
Guy's Hospital
European Society for Blood and Marrow Transplant Society

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
Bristol Myers Squibb International Corporation

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Bristol Myers Squibb International Corporation

VLAAMS BRABANT
MECHELEN

Berlin
ADDRESS: NOT PROVIDED - DE
TERGISS : Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis
Institution: Information not provided - DE

Nordrhein-Westfalen
LEVERKUSEN

Thüringen
JENA

ILE-DE-FRANCE
PARIS
Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Sanofi-aventis Groupe

Suisse Alémanique
BASEL
FocuSSced study: A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis
Hoffmann-La Roche
Hoffmann - La Roche Ltd.

Connecticut
WALLINGFORD
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis
Bristol-Myers Squibb Company
Bristol-Myers Squibb

Indiana
INDIANAPOLIS
BRAVE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus
Eli Lilly and Company World Headquarters

Massachusetts
ROCKLAND

Michigan
ANN ARBOR
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
University of Michigan UH B1 H410/0028
University of Michigan

Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis
Institution: Information not provided - US

Washington
ADDRESS: NOT PROVIDED - US
ISLAND-SLE: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Institution: Information not provided - US

Essex
HARLOW